KIORA PHARMACEUTICALS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
KIORA PHARMACEUTICALS, INC. (KPRX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-07-07.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-07-07
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $12.06K.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $12.06K, a 99.55% decline from fiscal 2019.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $2.69M, a 62.54% increase from fiscal 2018.
- KIORA PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $1.65M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K/A · filed 2022-07-07 | |||
| 2020-12-31 | $12.06K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-07 | $12.06K derived: sum of 2 quarters · filed 2022-07-07 | $12.06K derived: sum of 3 quarters · filed 2022-07-07 | $12.06K 10-K/A · filed 2022-07-07 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $2.69M 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $2.69M 10-Q · filed 2020-11-09 | $2.69M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $2.69M 10-Q · filed 2020-08-06 | $2.69M derived: sum of 3 quarters · filed 2020-08-06 | $3.00M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $2.69M 10-Q · filed 2020-05-06 | $2.69M derived: sum of 2 quarters · filed 2020-05-06 | $3.00M derived: sum of 3 quarters · filed 2020-05-06 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $314.50K derived: sum of 2 quarters · filed 2020-03-04 | $1.65M 10-K · filed 2020-03-04 | |
| 2018-09-30 | $314.50K 10-Q · filed 2019-11-07 | $1.65M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |